vs
Side-by-side financial comparison of Bio-Techne (TECH) and Tecnoglass Inc. (TGLS). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $245.3M, roughly 1.2× Tecnoglass Inc.). Bio-Techne runs the higher net margin — 12.8% vs 10.6%, a 2.2% gap on every dollar of revenue. On growth, Tecnoglass Inc. posted the faster year-over-year revenue change (2.4% vs -6.4%). Over the past eight quarters, Tecnoglass Inc.'s revenue compounded faster (12.8% CAGR vs 4.2%).
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
Tecnoglass Inc. is a leading manufacturer of high-performance architectural glass, aluminum windows, doors, and associated building components. It primarily caters to residential and commercial construction sectors across North America and Latin America, offering custom, energy-efficient solutions for new construction and renovation projects.
TECH vs TGLS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $245.3M |
| Net Profit | $38.0M | $26.1M |
| Gross Margin | 64.6% | 40.0% |
| Operating Margin | 18.4% | 18.3% |
| Net Margin | 12.8% | 10.6% |
| Revenue YoY | -6.4% | 2.4% |
| Net Profit YoY | 68.3% | -44.5% |
| EPS (diluted) | $0.24 | $0.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $295.9M | $245.3M | ||
| Q3 25 | — | $260.5M | ||
| Q2 25 | $317.0M | $255.5M | ||
| Q1 25 | $316.2M | $222.3M | ||
| Q4 24 | $297.0M | $239.6M | ||
| Q3 24 | $289.5M | $238.3M | ||
| Q2 24 | $306.1M | $219.7M | ||
| Q1 24 | $303.4M | $192.6M |
| Q4 25 | $38.0M | $26.1M | ||
| Q3 25 | — | $47.2M | ||
| Q2 25 | $-17.7M | $44.1M | ||
| Q1 25 | $22.6M | $42.2M | ||
| Q4 24 | $34.9M | $47.0M | ||
| Q3 24 | $33.6M | $49.5M | ||
| Q2 24 | $40.6M | $35.0M | ||
| Q1 24 | $49.1M | $29.7M |
| Q4 25 | 64.6% | 40.0% | ||
| Q3 25 | — | 42.7% | ||
| Q2 25 | 62.7% | 44.7% | ||
| Q1 25 | 67.9% | 43.9% | ||
| Q4 24 | 65.3% | 44.5% | ||
| Q3 24 | 63.2% | 45.8% | ||
| Q2 24 | 66.4% | 40.8% | ||
| Q1 24 | 67.4% | 38.8% |
| Q4 25 | 18.4% | 18.3% | ||
| Q3 25 | — | 25.1% | ||
| Q2 25 | -7.5% | 24.0% | ||
| Q1 25 | 12.2% | 26.7% | ||
| Q4 24 | 16.0% | 28.0% | ||
| Q3 24 | 13.8% | 28.4% | ||
| Q2 24 | 15.0% | 23.3% | ||
| Q1 24 | 22.1% | 21.3% |
| Q4 25 | 12.8% | 10.6% | ||
| Q3 25 | — | 18.1% | ||
| Q2 25 | -5.6% | 17.3% | ||
| Q1 25 | 7.1% | 19.0% | ||
| Q4 24 | 11.7% | 19.6% | ||
| Q3 24 | 11.6% | 20.8% | ||
| Q2 24 | 13.3% | 15.9% | ||
| Q1 24 | 16.2% | 15.4% |
| Q4 25 | $0.24 | $0.57 | ||
| Q3 25 | — | $1.01 | ||
| Q2 25 | $-0.11 | $0.94 | ||
| Q1 25 | $0.14 | $0.90 | ||
| Q4 24 | $0.22 | $1.00 | ||
| Q3 24 | $0.21 | $1.05 | ||
| Q2 24 | $0.26 | $0.75 | ||
| Q1 24 | $0.31 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.9M | $104.1M |
| Total DebtLower is stronger | $260.0M | $174.4M |
| Stockholders' EquityBook value | $2.0B | $713.1M |
| Total Assets | $2.5B | $1.3B |
| Debt / EquityLower = less leverage | 0.13× | 0.24× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.9M | $104.1M | ||
| Q3 25 | — | $127.1M | ||
| Q2 25 | $162.2M | $140.9M | ||
| Q1 25 | $140.7M | $160.2M | ||
| Q4 24 | $177.5M | $137.5M | ||
| Q3 24 | $187.5M | $124.8M | ||
| Q2 24 | $152.9M | $129.5M | ||
| Q1 24 | $145.3M | $138.8M |
| Q4 25 | $260.0M | $174.4M | ||
| Q3 25 | — | $114.7M | ||
| Q2 25 | $346.0M | $110.6M | ||
| Q1 25 | $330.0M | $110.6M | ||
| Q4 24 | $300.0M | $111.1M | ||
| Q3 24 | $300.0M | $126.8M | ||
| Q2 24 | $319.0M | $144.7M | ||
| Q1 24 | $389.0M | $160.9M |
| Q4 25 | $2.0B | $713.1M | ||
| Q3 25 | — | $764.0M | ||
| Q2 25 | $1.9B | $736.0M | ||
| Q1 25 | $2.0B | $685.1M | ||
| Q4 24 | $2.1B | $631.2M | ||
| Q3 24 | $2.1B | $613.3M | ||
| Q2 24 | $2.1B | $574.8M | ||
| Q1 24 | $2.0B | $573.6M |
| Q4 25 | $2.5B | $1.3B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $2.6B | $1.2B | ||
| Q1 25 | $2.6B | $1.1B | ||
| Q4 24 | $2.7B | $1.0B | ||
| Q3 24 | $2.7B | $996.3M | ||
| Q2 24 | $2.7B | $942.5M | ||
| Q1 24 | $2.7B | $981.6M |
| Q4 25 | 0.13× | 0.24× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | 0.18× | 0.15× | ||
| Q1 25 | 0.16× | 0.16× | ||
| Q4 24 | 0.14× | 0.18× | ||
| Q3 24 | 0.14× | 0.21× | ||
| Q2 24 | 0.15× | 0.25× | ||
| Q1 24 | 0.19× | 0.28× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $31.0M |
| Free Cash FlowOCF − Capex | — | $11.4M |
| FCF MarginFCF / Revenue | — | 4.7% |
| Capex IntensityCapex / Revenue | — | 8.0% |
| Cash ConversionOCF / Net Profit | — | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $34.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $31.0M | ||
| Q3 25 | — | $40.0M | ||
| Q2 25 | $98.2M | $17.9M | ||
| Q1 25 | $41.1M | $46.9M | ||
| Q4 24 | $84.3M | $61.1M | ||
| Q3 24 | $63.9M | $41.5M | ||
| Q2 24 | $75.5M | $34.5M | ||
| Q1 24 | $81.0M | $33.4M |
| Q4 25 | — | $11.4M | ||
| Q3 25 | — | $21.2M | ||
| Q2 25 | $93.3M | $-14.7M | ||
| Q1 25 | $31.0M | $16.5M | ||
| Q4 24 | $77.5M | $35.4M | ||
| Q3 24 | $54.7M | $17.8M | ||
| Q2 24 | $57.5M | $14.2M | ||
| Q1 24 | $64.5M | $23.6M |
| Q4 25 | — | 4.7% | ||
| Q3 25 | — | 8.2% | ||
| Q2 25 | 29.4% | -5.7% | ||
| Q1 25 | 9.8% | 7.4% | ||
| Q4 24 | 26.1% | 14.8% | ||
| Q3 24 | 18.9% | 7.5% | ||
| Q2 24 | 18.8% | 6.5% | ||
| Q1 24 | 21.3% | 12.2% |
| Q4 25 | — | 8.0% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | 1.5% | 12.7% | ||
| Q1 25 | 3.2% | 13.7% | ||
| Q4 24 | 2.3% | 10.7% | ||
| Q3 24 | 3.2% | 9.9% | ||
| Q2 24 | 5.9% | 9.2% | ||
| Q1 24 | 5.4% | 5.1% |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 0.85× | ||
| Q2 25 | — | 0.41× | ||
| Q1 25 | 1.82× | 1.11× | ||
| Q4 24 | 2.42× | 1.30× | ||
| Q3 24 | 1.90× | 0.84× | ||
| Q2 24 | 1.86× | 0.98× | ||
| Q1 24 | 1.65× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
TGLS
| Product Sales | $164.2M | 67% |
| Fixed Price Contracts | $81.1M | 33% |
| Related Party | $692.0K | 0% |
